Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
=== Cutaneous angiofibroma === These papule, nodule, and/or tumor lesions occur on the: 1) face and are typically termed fibrous papules; 2) penis and are typically termed pearly penile papules; and 3) underneath a fingernail or toenail and are typically termed periungual angiofibromas. Some of these cutaneous AGF lesions occur in individuals with one or more of 3 different genetic diseases: tuberous sclerosis, multiple endocrine neoplasia type 1, and Birt-Hogg-Dube syndrome. The following are examples of these cutaneous angiofibromas and their alternate names.
Early fossils that might represent animals appear for example in the 665-million-year-old rocks of the Trezona Formation of South Australia. These fossils are interpreted as most probably being early sponges. Trace fossils such as tracks and burrows found in the Tonian period (from 1 gya) may indicate the presence of triploblastic worm-like animals, roughly as large (about 5 mm wide) and complex as earthworms. However, similar tracks are produced by the giant single-celled protist Gromia sphaerica, so the Tonian trace fossils may not indicate early animal evolution. Around the same time, the layered mats of microorganisms called stromatolites decreased in diversity, perhaps due to grazing by newly evolved animals. Sterane biomarkers, which are usually indicative of demosponges, are found throughout the late Cryogenian and onward, but may also be produced by rhizarians. Objects such as sediment-filled tubes that resemble trace fossils of the burrows of wormlike animals have been found in 1.2 gya rocks in North America, in 1.5 gya rocks in Australia and North America, and in 1.7 gya rocks in Australia. Their interpretation as having an animal origin is disputed, as they might be water-escape or other structures.
=== X-ray spectrometer === The most practical application of 244Cm—though rather limited in total volume—is as an α-particle source in alpha particle X-ray spectrometers (APXS). These instruments were installed on the Sojourner, Mars, Mars 96, Mars Exploration Rovers and Philae comet lander, as well as the Mars Science Laboratory to analyze the composition and structure of the rocks on the surface of planet Mars. APXS was also used in the Surveyor 5–7 moon probes but with a 242Cm source. An elaborate APXS setup has a sensor head containing six curium sources with a total decay rate of several tens of millicuries (roughly one gigabecquerel). The sources are collimated on a sample, and the energy spectra of the alpha particles and protons scattered from the sample are analyzed (proton analysis is done only in some spectrometers). These spectra contain quantitative information on all major elements in the sample except for hydrogen, helium and lithium.
AlphaFold 2 (2021) demonstrated the ability to approximate, in hours rather than months, the 3D structure of a protein. In 2023, it was reported that AI-guided drug discovery helped find a class of antibiotics capable of killing two different types of drug-resistant bacteria. In 2024, researchers used machine learning to accelerate the search for Parkinson's disease drug treatments. Their aim was to identify compounds that block the clumping, or aggregation, of alpha-synuclein (the protein that characterises Parkinson's disease). They were able to speed up the initial screening process ten-fold and reduce the cost by a thousand-fold. A 2026 Nature article titled "Dozens of AI disease-prediction models were trained on dubious data" highlighted the use of unreliable data being used to train AI medical prediction models for stroke and diabetes in 125 research articles. Evidence suggested some of the AI tools that were developed on unreliable data had been used on patients, although it was not clear if there were adverse outcomes.
Sources: en.wikipedia.org
== Clinical significance == Myositis may cause thickening of the muscle fascicles. This may be detected with ultrasound scans. Muscle fascicle structure is a useful diagnostic tool for dermatomyositis. Myocytes towards the edges of the muscle fascicle are typically narrower, while those at the centre of the muscle fascicle are a normal thickness. Muscle fascicles may be involved in myokymia, although commonly only individual myocytes are involved.
Following Donald Trump's victory in the 2024 U.S. presidential election, several prominent tech industry figures expressed support for positions aligned with effective accelerationism, particularly regarding deregulation and technological advancement. The potential appointment of Elon Musk to government roles focused on auditing federal programs drew support from venture capitalists who anticipated reduced regulatory oversight of the technology sector. Notable tech figures publicly connected these developments to the movement's principles. Aaron Levie, CEO of Box, expressed support for "removing unnecessary red tape and over-regulation", while Mark Pincus, early Facebook investor and Zynga founder, explicitly referenced "effective accelerationism" in his post-election commentary. Venture capitalists viewed the incoming administration as an opportunity to ease regulations that had affected technology mergers and acquisitions during the previous years.
The original Pennsylvania Station was an ornate station building designed by McKim, Mead, and White and considered a masterpiece of the Beaux-Arts style. Completed in 1910, it enabled direct rail access to New York City from the south for the first time. Its head house and train shed were torn down in 1963 at a time of low train ridership, with the rail infrastructure reconstituted as the smaller underground station that survives today. The New York Times editorial board described the demolition of the original station as a "monumental act of vandalism", and its destruction galvanized the modern historic preservation movement. As rail travel increased again in the following decades, the underground station began to operate beyond its design capacity. By 2015, the station handled 650,000 travelers daily (more than the region's three major airports combined) and had become loathed for its cramped, claustrophobic conditions. The 2020s saw the opening of Moynihan Train Hall, a head house that expanded Penn Station into the Farley building, as well as expansion of the LIRR concourse and a new direct entrance from 33rd Street. Plans under development call for reconstruction of the core of the station, with competing proposals regarding the station's relationship to Madison Square Garden under consideration. Looking back on the pace of reconstruction since the announcement of Moynihan Hall in 1999, the Times noted in 2025 that "More than 25 years, five presidencies and four governors later, the plan to rebuild Penn Station is nowhere near completion."
== Career == Townsend held various academic positions at the Medical University of South Carolina, starting as a Research Assistant Professor (2004) in the Department of Pharmaceutical Sciences. She was appointed as an associate professor in the Drug Discovery and Biomedical Sciences department in 2015 and has been serving as a Professor and acting department chair. In 2021, Townsend became the co-director of the Administrative Core for the Redox COBRE.
== Illness and death == In June 2026, Chase was admitted to the Los Angeles General Medical Center for treatment of severe malnutrition following a period of extreme weight loss. During her hospitalization, her condition became increasingly critical after she was diagnosed with bacterial meningitis, several bloodstream infections, and AIDS. Doctors stated that she did not have much time left to live. To help manage rising medical expenses and support Chase in regaining stability, her alleged boyfriend, Roy Hernandez, created a GoFundMe crowdfunding campaign. In the campaign description, Hernandez said that Chase had faced significant personal difficulties in her post-acting life, including systemic bullying, a painful estrangement from her family, and ongoing housing instability in downtown Los Angeles. Chase died hours after the fundraising page was launched on June 16, from organ failure caused by her infections, substance abuse and AIDS. She was 35. A secondary cause of death was chronic polysubstance use. Hernandez publicly announced her death through TMZ the following day, June 17, stating that her bloodstream infections had led to septic complications that caused her body to shut down. Following her death, a dispute emerged regarding her final arrangements and the crowdfunding campaign, which Hernandez claimed was intended to help fund her cremation. Chase's former manager, John Ryan, and her father, John Schwallier, publicly denounced the fundraiser, advising fans not to donate.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.